Terms: = Endocrine gland cancer AND MLH1, COCA2, 4292, ENSG00000076242, hMLH1, FCC2, HNPCC2, P40692, MGC5172, HNPCC AND Clinical Outcome
15 results:
1. Genetic polymorphisms in
Si W; Kang S; Sun H; Chen J; Cao S; Li Y
Int J Gynecol Cancer; 2019 Sep; 29(7):1148-1155. PubMed ID: 31273068
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas.
Wong KS; Lorch JH; Alexander EK; Nehs MA; Nowak JA; Hornick JL; Barletta JA
Thyroid; 2019 May; 29(5):666-673. PubMed ID: 30869569
[No Abstract] [Full Text] [Related]
3. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract] [Full Text] [Related]
4. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma.
Riazy M; Kalloger SE; Sheffield BS; Peixoto RD; Li-Chang HH; Scudamore CH; Renouf DJ; Schaeffer DF
Mod Pathol; 2015 Oct; 28(10):1383-9. PubMed ID: 26226846
[TBL] [Abstract] [Full Text] [Related]
5. clinical implications of microsatellite instability and mlh1 gene inactivation in sporadic insulinomas.
Mei M; Deng D; Liu TH; Sang XT; Lu X; Xiang HD; Zhou J; Wu H; Yang Y; Chen J; Lu CM; Chen YJ
J Clin Endocrinol Metab; 2009 Sep; 94(9):3448-57. PubMed ID: 19567531
[TBL] [Abstract] [Full Text] [Related]
6. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.
Dong X; Jiao L; Li Y; Evans DB; Wang H; Hess KR; Abbruzzese JL; Li D
J Clin Oncol; 2009 Apr; 27(10):1592-9. PubMed ID: 19237629
[TBL] [Abstract] [Full Text] [Related]
7. Pharmaco(epi)genomics in ovarian cancer.
Paige AJ; Brown R
Pharmacogenomics; 2008 Dec; 9(12):1825-34. PubMed ID: 19072641
[TBL] [Abstract] [Full Text] [Related]
8. Mismatch repair expression in testicular cancer predicts recurrence and survival.
Velasco A; Corvalan A; Wistuba II; Riquelme E; Chuaqui R; Majerson A; Leach FS
Int J Cancer; 2008 Apr; 122(8):1774-7. PubMed ID: 18076065
[TBL] [Abstract] [Full Text] [Related]
9. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Chiang JW; Karlan BY; Cass L; Baldwin RL
Gynecol Oncol; 2006 Jun; 101(3):403-10. PubMed ID: 16360812
[TBL] [Abstract] [Full Text] [Related]
10. Hereditary ovarian cancer.
Prat J; Ribé A; Gallardo A
Hum Pathol; 2005 Aug; 36(8):861-70. PubMed ID: 16112002
[TBL] [Abstract] [Full Text] [Related]
11. [Immunohistochemical and molecular analyis of mismatch repair genes in germ cell tumors].
Velasco Palma A; Riquelme Sánchez E; Schulze Maroto M; Villarroel del Pino L; Leach FS
Actas Urol Esp; 2005 Feb; 29(2):198-206. PubMed ID: 15881919
[TBL] [Abstract] [Full Text] [Related]
12. Osteoclast-like giant cell tumor in mucinous cystadenocarcinoma of the pancreas: an immunohistochemical and molecular analysis.
Sedivy R; Kalipciyan M; Mazal PR; Wolf B; Wrba F; Karner-Hanusch J; Mühlbacher F; Mader RM
Cancer Detect Prev; 2005; 29(1):8-14. PubMed ID: 15734212
[TBL] [Abstract] [Full Text] [Related]
13. Loss of hmlh1 expression correlates with improved survival in stage III-IV ovarian cancer patients.
Scartozzi M; De Nictolis M; Galizia E; Carassai P; Bianchi F; Berardi R; Gesuita R; Piga A; Cellerino R; Porfiri E
Eur J Cancer; 2003 May; 39(8):1144-9. PubMed ID: 12736115
[TBL] [Abstract] [Full Text] [Related]
14. Hereditary risk of women's cancers.
Frank TS; Critchfield GC
Best Pract Res Clin Obstet Gynaecol; 2002 Oct; 16(5):703-13. PubMed ID: 12475549
[TBL] [Abstract] [Full Text] [Related]
15. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity.
Risinger JI; Umar A; Boyer JC; Evans AC; Berchuck A; Kunkel TA; Barrett JC
Cancer Res; 1995 Dec; 55(23):5664-9. PubMed ID: 7585651
[TBL] [Abstract] [Full Text] [Related]